Alkermes Plc news

   Watch this stock
Showing stories 1 - 10 of about 97   

Articles published

ALKS 47.32 +1.19 (2.58%)
price chart
Analyst's Report Recap: Alkermes (ALKS)
The mean price target for the shares of Alkermes Plc (NASDAQ:ALKS) is at $45.73 while the highest price target suggested by the analysts is $59.00 and low price target is $31.00.
Upgrades And Downgrades For Alkermes Plc (NASDAQ:ALKS)  Risers & Fallers
Alkermes Plc (NASDAQ:ALKS) Begins New Study As Acorda Therapeutics, Inc ...
Alkermes Plc (NASDAQ:ALKS) has begun studies on its cancer immunotherapy drug ALKS 4230. Formerly referred to as RDB 1450, this drug will be studied for its immunological- pharmacodynamic effects in the treatment of solid tumors.
Healthcare Stocks Review: Shire plc (NASDAQ:SHPG) , Alkermes plc (NASDAQ:ALKS)  Is stories
Alkermes Plc (NASDAQ:ALKS) Latest Broker Coverage  Risers & Fallers
Alkermes plc (ALKS) Commences ALKS 4230 Phase 1
Alkermes plc (Nasdaq: ALKS) announced the initiation of a phase 1 clinical study of the company's immuno-oncology drug candidate, ALKS 4230 (formerly referred to as RDB 1450), a novel Selective Effector Cell Activator (SECA™) protein designed for ...
Alkermes Initiates Phase 1 Clinical Trial Of Immuno-Oncology Drug Candidate ...  Benzinga
Alkermes plc (NASDAQ:ALKS) Daily Sentiment Score Of -0.203
Alkermes plc (NASDAQ:ALKS) has a daily sentiment score of -0.203. This score is given by Alpha One, which uses its self-designed algorithm to identify market sentiment on the stock after studying the published content on the web.
Alkermes plc (NASDAQ:ALKS) Boast 1-Year Price Target Of $57.8
As of 2016-05-29, Alkermes plc (NASDAQ:ALKS) stock has an ABR of 1.88. This value was reached after accounting the price forecasts of 5 brokerages.
BRIEF-Alkermes Plc starts Phase 1 clinical study of immuno-oncology drug candidate
May 25 Alkermes Plc. * Initiation of phase 1 clinical study of immuno-oncology drug candidate ALKS 4230. * Initial results from first stage of phase 1 study are expected in 2017.
Alkermes Plc (ALKS) Ascent Sends Options Volume to the Moon
A number of drug stocks are making moves higher, and biotech Alkermes Plc (NASDAQ:ALKS) is no exception amid unsubstantiated takeover talk.
Alkermes Plc Stock Was Bought By Options Traders  Franklin Independent
Alkermes plc (NASDAQ:ALKS) Closes At $42.98  Vanguard Tribune
Notable HC Stocks Preview: Alkermes Plc (NASDAQ:ALKS), Perrigo Company plc ...
Shares of Alkermes Plc (NASDAQ:ALKS) ended Friday session in green amid volatile trading. The shares closed up +1.84 points or 4.15% at $46.13 with 1.29 million shares getting traded.
Alkermes plc Reports Financial Results for the Year Ended Dec. 31, 2015 and ...
Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases.
Alkermes Plc (ALKS) Richard F. Pops on Q4 2015 Results - Earnings Call ...  Seeking Alpha
Alkermes Q4 Loss Narrower than Expected, Updates Pipeline
Analyst Review on Two Buzzers: CVS Health Corporation (NYSE:CVS), Alkermes plc ...
CVS Health Corporation (NYSE:CVS) went lower by -0.01% to close at $ 96.94. The company exchanged total volume of 4.44 million shares throughout course of last trade however it holds an average trading capacity of 4.31 million shares.